🔎 Trials Near Me

Home › Myelofibrosis › North Carolina

Myelofibrosis clinical trials in North Carolina

17 studies for Myelofibrosis are looking for participants at sites in North Carolina.

Cities in North Carolina

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • Atrium Health Cabarrus/LCI-Concord, Concord
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06661915

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

  • Atrium Health Wake Forest Baptist, Winston-Salem
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT05320198

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

  • Duke Cancer Institute, Durham
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT04176198

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  • Duke Blood Cancer Center, Durham
  • Novant Health, Winston-Salem
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT07623161

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

  • University of North Carolina At Chapel Hill, Chapel Hill
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT07008118

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

  • University of North Carolina At Chapel Hill, Chapel Hill
  • Levine Cancer Institute, Charlotte
  • Duke University Medical Center, Department of Hematologic Malignancies and Cellular Therapy, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT07441694

Registry of Older Patients With Cancer

  • Seby B. Jones Cancer Center, Boone
  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
  • East Carolina University, Greenville
  • and 4 more
RecruitingObservational study
Ages 65 and older · All sexes · Updated Jun 29, 2026 · NCT01137825

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

  • Wake Forest Baptist Health Comprehensive Cancer Center, Winston-Salem
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT05835466

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

  • University of North Carolina, Chapel Hill
RecruitingPhase 1
Ages 13 and older · All sexes · Updated May 5, 2026 · NCT04771572

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

  • Wake Forest Baptist Medical Center, Winston-Salem
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 17, 2026 · NCT06034002

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

  • DUHS Duke Blood Cancer Center ( Site 6005), Durham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Apr 2, 2026 · NCT06351631

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

  • Duke University, Durham
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 12, 2026 · NCT05980806

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Chapel Hill
  • Massive Bio SYNERGY-AI site, Winston-Salem
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Oct 27, 2025 · NCT01137643

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

  • Medical University of South Carolina (MUSC), Charleston
  • Atrium Health Levine Cancer Institute, Charlotte
  • Duke University Medical Center, Durham
  • and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2025 · NCT06479135

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.